Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fastly Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Fastly Inc trades at $28.5 (market cap $4.58B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.5× Fastly Inc's market cap, and Fastly Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FSLY | |
|---|---|---|
Market Cap | $29.60B | $4.58B |
Sector | Health | Technology |
52-Week High | $491.22 | $33.50 |
52-Week Low | $205.48 | $6.85 |
Enterprise Value | $27.56B | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Fastly (FSLY) trades at $28.59, up 3.03% today, with strong technical momentum and bullish moving averages. The company reported consecutive earnings beats, with Q2 2026 EPS of $0.15 surpassing estimates, and raised its 2026 outlook driven by security and AI demand. Revenue growth is robust at 23% year-over-year, though the company remains unprofitable with a net income margin of -11.8%.
The outlook is positive given accelerating revenue growth and strategic positioning in edge cloud and AI infrastructure, but risks include persistent losses, high valuation multiples, and competitive pressures. Analyst consensus is cautious with a hold-heavy rating and a $28.25 price target, slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
